{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:52:37Z","timestamp":1791924757166,"version":"4.3.4"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"31","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>The use of immune checkpoint inhibitors (ICIs) has greatly improved the outcomes of cancer. However, ICI-induced immune-related adverse events have been reported, among which neurological immune-related adverse events are rare but potentially life-threatening. To analyze the characteristics of ICI-induced inflammatory disease of the central nervous system (CNS), we reported the first case induced by tislelizumab and conducted a systematic review of 33 cases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 65-year-old male patient who received 4 cycles of tislelizumab for lung squamous carcinoma developed myelitis, demyelinating encephalopathy, and peripheral neuropathy overlap syndrome. Case reports and case series that described ICI-associated inflammatory disease of the CNS in the PubMed and Embase databases were searched up to October 2022.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The patient was diagnosed with ICI-associated neuroimmune overlap syndrome, including myelitis, peripheral neuropathy, and multifocal demyelinating encephalopathy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient was treated with intravenous methylprednisolone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The symptoms alleviated gradually. Twenty-six publications that described 33 cases with ICI-associated inflammatory disease of the CNS were reviewed. In addition to the present case, only 8 cases with both brain and spinal cord lesions induced by ICIs were reported. Intravenous steroids were the first-line therapy, while plasmapheresis, intravenous immunoglobulin, cyclophosphamide, and some monoclonal antibodies may be effective for steroid-refractory neurological immune-related adverse events. Thirteen patients experienced relapse, and 4 patients died, one of whom committed suicide.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>ICI-associated inflammatory disease of the CNS is very rare, but we should be aware of and detect it to treat timely manner and achieve a good prognosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000043552","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T23:01:00Z","timestamp":1754089260000},"page":"e43552","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Immune checkpoint inhibitors associated inflammatory disease of central nervous system: Case report and systemic review"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9730-4566","authenticated-orcid":false,"given":"Ting-Ting","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pen-Ju","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8953-0005","authenticated-orcid":false,"given":"Guang-Zhi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250918","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics.","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J"},{"key":"R2-20250918","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors.","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R3-20250918","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"R4-20250918","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature.","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"key":"R5-20250918","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review.","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"key":"R6-20250918","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40265-020-01286-z","article-title":"Tislelizumab: first approval.","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"R7-20250918","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1080\/13543784.2020.1833857","article-title":"Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC).","volume":"29","author":"Liu","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"R8-20250918","doi-asserted-by":"crossref","first-page":"899971","DOI":"10.3389\/fimmu.2022.899971","article-title":"Imaging mass cytometry analysis of immune checkpoint inhibitor-related pneumonitis: a case report.","volume":"13","author":"Cheng","year":"2022","journal-title":"Front Immunol"},{"key":"R9-20250918","doi-asserted-by":"crossref","first-page":"10186","DOI":"10.12998\/wjcc.v10.i28.10186","article-title":"Tislelizumab-related enteritis successfully treated with adalimumab: a case report.","volume":"10","author":"Chen","year":"2022","journal-title":"World J Clin Cases"},{"key":"R10-20250918","doi-asserted-by":"crossref","first-page":"664809","DOI":"10.3389\/fonc.2021.664809","article-title":"Immune-related multiple-organs injuries following ICI treatment with tislelizumab in an advanced non-small cell lung cancer patient: a case report.","volume":"11","author":"Deng","year":"2021","journal-title":"Front Oncol"},{"key":"R11-20250918","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R12-20250918","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/1078155215572932","article-title":"Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: a case report and review of literature.","volume":"22","author":"Abdallah","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"R13-20250918","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejca.2020.12.014","article-title":"Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin alpha4 therapy.","volume":"145","author":"Basin","year":"2021","journal-title":"Eur J Cancer"},{"key":"R14-20250918","doi-asserted-by":"crossref","first-page":"e002732","DOI":"10.1136\/jitc-2021-002732","article-title":"Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis.","volume":"9","author":"Bjursten","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R15-20250918","doi-asserted-by":"crossref","first-page":"100324","DOI":"10.1016\/j.ensci.2021.100324","article-title":"Detect it so you can treat it: a case series and proposed checklist to detect neurotoxicity in checkpoint therapy.","volume":"22","author":"Bolz","year":"2021","journal-title":"eNeurologicalSci"},{"issue":"Suppl 15","key":"R16-20250918","article-title":"A case report of recurrent longitudinally extensive holocord transverse myelitis after combination immune checkpoint inhibitor therapy with nivolumab and ipilimumab.","volume":"94","author":"Brahmbhatt","year":"2020","journal-title":"Neurology"},{"key":"R17-20250918","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s40425-018-0471-2","article-title":"Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation.","volume":"6","author":"Chang","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"R18-20250918","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1177\/1352458518803724","article-title":"Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma.","volume":"25","author":"Dur\u00e3es","year":"2019","journal-title":"Mult Scler"},{"issue":"Suppl 2","key":"R19-20250918","article-title":"Checkpoint inhibitor-induced longitudinally extensive transverse myelitis: a report on two cases.","volume":"25","author":"Makkawi","year":"2019","journal-title":"Multi Scler"},{"key":"R20-20250918","doi-asserted-by":"crossref","first-page":"e967","DOI":"10.1212\/NXI.0000000000000967","article-title":"Longitudinally extensive myelitis associated with immune checkpoint inhibitors.","volume":"8","author":"Picca","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R21-20250918","doi-asserted-by":"crossref","first-page":"101447","DOI":"10.1016\/j.msard.2019.101447","article-title":"Neuromyelitis optica spectrum disorder after treatment with pembrolizumab.","volume":"37","author":"Shimada","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"R22-20250918","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12885-018-3997-2","article-title":"Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report.","volume":"18","author":"Narumi","year":"2018","journal-title":"BMC Cancer"},{"key":"R23-20250918","doi-asserted-by":"crossref","first-page":"655283","DOI":"10.3389\/fneur.2021.655283","article-title":"Case report: longitudinal extensive transverse myelitis with novel autoantibodies following two rounds of pembrolizumab.","volume":"12","author":"Charabi","year":"2021","journal-title":"Front Neurol"},{"key":"R24-20250918","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2019.4379","article-title":"CRMP5-IgG-associated paraneoplastic myelopathy with PD-L1 inhibitor therapy.","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol"},{"key":"R25-20250918","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s40425-019-0818-3","article-title":"Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.","volume":"7","author":"Pillonel","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"R26-20250918","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2217\/imt-2020-0186","article-title":"Asymptomatic brainstem lesions and pachymeningeal enhancement after anti-PD-1 therapy.","volume":"13","author":"Yuen","year":"2021","journal-title":"Immunotherapy"},{"issue":"Suppl 4","key":"R27-20250918","article-title":"Encephalopathy following treatment with pembrolizumab for metastatic non-small cell lung cancer: a case report.","volume":"12","author":"Feng","year":"2016","journal-title":"Asia Pac J Clin Oncol"},{"key":"R28-20250918","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro Oncol"},{"key":"R29-20250918","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12883-022-02576-7","article-title":"Longitudinal extensive transverse myelitis after chemoradiation therapy with durvalumab, a rare complication: case report.","volume":"22","author":"Moodie","year":"2022","journal-title":"BMC Neurol"},{"key":"R30-20250918","doi-asserted-by":"crossref","first-page":"102451","DOI":"10.1016\/j.msard.2020.102451","article-title":"Is neuromyelitis optica without AQP4-IgG a T-cell mediated disease? Insights from checkpoint inhibitor immune-related adverse events.","volume":"46","author":"Nasralla","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"R31-20250918","doi-asserted-by":"crossref","first-page":"e773","DOI":"10.1212\/NXI.0000000000000773","article-title":"Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors.","volume":"7","author":"Nowosielski","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R32-20250918","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1159\/000368316","article-title":"Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma.","volume":"37","author":"O\u2019Kane","year":"2014","journal-title":"Oncol Res Treat"},{"key":"R33-20250918","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1016\/j.cllc.2022.08.012","article-title":"Combination intravenous immune globulin (IVIG) and high dose steroids for treatment of immune-related myelitis in a non-small cell lung cancer patient treated with pembrolizumab and palliative radiation treatment: a case report.","volume":"23","author":"Owen","year":"2022","journal-title":"Clin Lung Cancer"},{"issue":"Suppl 1","key":"R34-20250918","article-title":"Hunting the real culprit: a complex case of nivolumab-related myelitis.","volume":"92","author":"Poretto","year":"2019","journal-title":"Neurology"},{"key":"R35-20250918","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ejca.2017.09.026","article-title":"Immune checkpoint inhibitor associated CNS autoimmune disorder (ICICAD) following nivolumab treatment: a new entity of drug-induced autoimmune encephalitis?","volume":"87","author":"Strik","year":"2017","journal-title":"Eur J Cancer"},{"key":"R36-20250918","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acn3.547","article-title":"Seronegative antibody-mediated neurology after immune checkpoint inhibitors.","volume":"5","author":"Wilson","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"issue":"Suppl 14","key":"R37-20250918","article-title":"Recurrent opticospinal inflammatory disease in association to ipilimumab.","volume":"84","author":"Zabad","year":"2015","journal-title":"Neurology"},{"key":"R38-20250918","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2174\/1570159X19666201230151224","article-title":"Immune checkpoint inhibitors and neurotoxicity.","volume":"19","author":"Zhao","year":"2021","journal-title":"Curr Neuropharmacol"},{"key":"R39-20250918","doi-asserted-by":"crossref","first-page":"e002890","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.","volume":"9","author":"Guidon","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"R40-20250918","doi-asserted-by":"crossref","first-page":"102189","DOI":"10.1016\/j.ctrv.2021.102189","article-title":"Neurological complications of cancer immunotherapy.","volume":"97","author":"Roth","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"R41-20250918","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy.","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R42-20250918","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.","volume":"7","author":"Das","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"R43-20250918","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.4049\/jimmunol.0803557","article-title":"Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity.","volume":"182","author":"Phares","year":"2009","journal-title":"J Immunol"},{"key":"R44-20250918","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series.","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"key":"R45-20250918","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"R46-20250918","doi-asserted-by":"crossref","first-page":"ltac012","DOI":"10.1093\/immadv\/ltac012","article-title":"Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?","volume":"2","author":"Katsumoto","year":"2022","journal-title":"Immunother Adv"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T22:00:50Z","timestamp":1758232850000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":46,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043552","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"2024-07-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}